Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development
• Phase 3 trial in liver cancer on track to start this quarter
• Two exploratory trials have been initiated
• Combination trials with immune checkpoint inhibitors planned to start in 2016
Strasbourg, France, November 12, 2015 – Transgene SA (Euronext: TNG) and SillaJen, Inc. today announced that they have signed an amended agreement for the development and commercialization of oncolytic viral therapy Pexa-Vec to streamline the conduct of clinical trials and to reflect important areas of interest for each company. Key changes to the agreement are outlined below.
1) Management and funding of the Phase 3 trial (PHOCUS) in hepatocellular carcinoma (HCC). SillaJen will assume responsibility for conducting the trial. Transgene remains responsible for submitting for marketing approval and retains commercialization rights in its territories. In return, Transgene will pay a total of $6 million to SillaJen over four years beginning this year. Under the terms of the original contract, Transgene was responsible for the development costs in its licensed territories.
0 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer